Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3565-3570

  Sourla, Antigone ^a   Lembessis, Panayiotis ^a   Mitsiades, Constantine ^a   Dimopoulos, Theodoros ^a   Skouteris, Michael ^a   Metsinis, Marios ^a   Ntounis, Athanassios ^a   Ioannidis, Apostolos ^a   Katsoulis, Athanassios ^a   Kyragiannis, Vassilis ^a   Lambou, Theocharis ^a   Tsintavis, Athanassios ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Androgen ablation therapy; Nested rt PCR; Prostate cancer; PSA; PSMA

Indexed keywords

ANDROGEN; ANTIANDROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRIPTORELIN;

ARTICLE; BLOOD; BONE MARROW BIOPSY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANDROGEN ANTAGONISTS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; CARBOXYPEPTIDASES; DISEASE-FREE SURVIVAL; FLUTAMIDE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIPTORELIN;

EID: 0035568940     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival
2. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer
3. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer
4. Identification of bone metastases in patients with prostate cancer
5. Molecular staging of prostate cancer. II. A comparison of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen
6. Enhanced reverse transcriptase-polymerase chain reaction as an indicator of true pathologic stage in patients with prostate cancer
7. Combined nested rt-PCR assay for prostate specific antigen and prostate specific membrane antigen in prostate cancer patients: Correlation with pathologic stage
8. The use of rt-PCR for prostate specific antigen assay to predict surgical failures before radical prostatectomy: Molecular staging of the prostate cancer
9. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostate-specific membrane reverse transcriptase polymerase chain reaction
10. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate
11. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse trancriptase polymerase chain reaction assay based on prostate specific membrane antigen
12. Hematogenous dissemination of prostatic epithelial cells during radical prostatectomy
13. The molecular concept of prostate cancer
14. Constitutive expression of high levels of prostate specific antigen in the absence of prostate carcinoma
15. The expression of prostate-specific membrane antigen in peripheral blood leukocytes
16. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in peripheral blood cells: Implications for the detection of hematogenous prostate cells and standardization
17. Repetitive and site-specific molecular staging using reverse-transcriptase polymarase chain reaction for prostate specific antigen and prostate specific membrane antigen at peripheral blood and bone marrow biopsy in prostate cancer patients
18. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
19. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin-apoptosis
20. Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors
21. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer
22. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: Development of an anti-survival factor therapy for hormone-refractory prostate cancer